Luba is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba serves as the Managing Partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. She is also the CEO of one of BSC’s portfolio companies Kojin Therapeutics, which is discovering and developing novel therapeutics in oncology, fibrosis, and immune modulation. She is a professor at Harvard University in the School of Engineering and Applied Sciences. Luba has previously served in leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub. Luba has led $5B+ in deals and investments across multiple therapeutic areas and life sciences and tech sectors globally. She has also co-founded biotech and digital health companies in the immunotherapy, AI/ML, women's health and microbiome space, including Luca Biologics. She has served on multiple public, private, and non-profit boards, including the Massachusetts Biotechnology Council (MassBio), Kojin Tx, Brooklyn ImmunoTherapeutics, BenchSci, In8Bio, and OS Fund, a SPAC. She has advised leading academic centers globally including the CEO of the Dana-Farber Cancer Institute as well as the Director of the Wyss Center for Bio and Neuroengineering in Geneva. She is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst and serves on Investor Committee for the National Cancer Institute. Luba is also a former litigator and regulatory, policy, and IP expert, having started her career at Wilmer Cutler Pickering Hale and Dorr. She is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.

Skip Kelly is a managing director and relationship executive in the Venture Capital (VC) coverage group for J.P. Morgan Commercial Banking. Comprised of venture experts with deep connectivity to the Innovation Economy, Skip joins the group committed to creating a supportive ecosystem for VC firms and their portfolio companies. To address the unique and holistic needs of VCs, he partners closely with Life Science and Healthcare relationship bankers to deliver global solutions to their portfolio companies across every stage of growth. In his role, Skip is also responsible for developing relationships at the national level with key VC firms from his location in Boston. Skip joined J.P. Morgan in January 2021, after 17 years with Silicon Valley Bank. He has worked in a number of roles including technology, advisory services/special assets and life sciences and healthcare. Most recently, he was Head of US Credit Solutions where he and team developed a host of creative debt financing solutions for all sectors across Life Science and Healthcare – Biotechnology, Diagnostics, Tools, Medical Device and Healthcare IT. Skip earned a bachelor’s degree in finance from Boston College. After growing up in the hospitality business in Southern Maine, good food and good company is still a passion. Skip, his wife and their three kids make their home in Andover, MA.

David is the Co-founder, President and Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience and has played an integral role in launching, building and operating many successful companies in the life sciences and other innovation sectors. Previously, David was the President and Chief Executive Officer of Entrega Bio, a PureTech Health company developing an innovative capsule technology to make injectable substances available orally. David’s first MIT-based startup was Semprus BioSciences, a biomedical company that went from business concept, to FDA 510(k) clearance and CE Mark approval, to major acquisition in five years. Semprus won the MIT $100K Entrepreneurial Competition for its business plan to develop a novel platform technology for reducing complications associated with long-term medical device implants, such as thrombosis and microbial adhesion. David subsequently led Semprus’ closing on several large financings before the company was acquired by Teleflex in 2012. Prior to Semprus, David was a Senior Executive at the leading venture capital firm, Polaris Partners, where he was responsible for deal-sourcing and originating and the execution of Polaris’ investment in Athletes Performance, a leading training facility for NFL, MLB, NHL and NBA professional athletes.